24 unknown, 10 recruiting, 6 active not recruiting, 5 not yet recruiting. 37 Phase 2, 11 Phase 1, 5 Phase 3, 2 Early Phase 1, 2 Not applicable.
Follow penpulimab: new trials by email Literature Review of penpulimab trials Research Report on penpulimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| R-MA-PD-1 Versus R-MA in Treatment-naive Primary CNS Lymphoma Penpulimab, Rituximab, Methotrexate - Primary Central Nervous System Lymphoma, Diffuse Large B-Cell Lymphoma | Not applicable | Not yet recruiting | WEI XU | 58 | 2026-08-01 | 2026-08-14 |
| Metronomic Oral Paclitaxel Plus PD-1/ PD-L1 Inhibitor Maintenance in Advanced Lung Cancer (PULSE Study) Paclitaxel Oral Solution, PD-1/PD-L1 inhibitor (eg. Tislelizumab) - Squamous Non-Small Cell Lung Cancer sqNSCLC, Extensive-stage Small Cell Lung Cancer (ES-SCLC) | Phase 4 | Recruiting | Anhui Provincial Cancer Hospital | 107 | 2026-07-24 | 2026-08-04 |
| A Phase II Clinical Trial of Anti-EGFR Antibody-drug Conjugate (ADC) Combined With or Without Immune Checkpoint Inhibitors in the Neoadjuvant Treatment of Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma Becotatug Vedotin, Becotatug Vedotin Combined with Penpulimab, Becotatug Vedotin Combined with Ivonescimab - Head and Neck Squamous Cell Carcinoma | Phase 2 | Recruiting | West China Hospital | 90 | 2026-07-20 | 2026-09-11 |
| Preoperative Radiotherapy and Anlotinib With or Without Penpulimab for Soft Tissue Sarcoma Anlotinib, Penpulimab, Preoperative Radiotherapy - Soft Tissue Sarcoma (STS) | Phase 2 | Not yet recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 274 | 2026-07-01 | 2026-05-28 |
| JDB153 Combined With Penpulimab for Hepatocellular Carcinoma After Standard Treatment Failure JDB153, Penpulimab - Refractory Hepatocellular Carcinoma | Phase 1 / Phase 2 | Not yet recruiting | West China Hospital | 10 | 2025-08-01 | 2025-07-20 |
| AK129 Combination Therapy for Advanced Solid Tumors AK129(dose 1), Pemetrexed, Paclitaxel - Non-small Cell Lung Cancer Stage IIIB/IV, Head and Neck Squamous Cell Carcinoma (HNSCC) | Phase 1 / Phase 2 | Recruiting | Akeso | 230 | 2025-05-21 | 2025-06-03 |
| Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C LM-108 injection, Penpulimab injection, Paclitaxel for injection (albumin bound) - Advanced Pancreatic Cancer | Phase 1 / Phase 2 | Recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 72 | 2025-04-11 | 2026-03-10 |
| Clinical Studies for the Treatment of Advanced Solid Tumors LM-108 injection+Penpulimab+ Oxaliplatin+Capecitabine, Tislelizumab+Oxaliplatin+Capecitabine, LM-108 injection 10mg/kg +penpulimab - Advanced Solid Tumor | Phase 1 / Phase 2 | Recruiting | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | 194 | 2025-04-08 | 2025-12-18 |
| Chemotherapy With the Ralox Regimen Combined With Anlotinib and Penpulimab for Unresectable Hepatocellular Carcinoma Intravenous chemotherapy with the Ralox regimen combined with Anlotinib and Penpulimab - Hepatocellular Carcinoma Non-Resectable | Early Phase 1 | Active not recruiting | Nanfang Hospital, Southern Medical University | 30 | 2025-01-01 | 2026-08-05 |
| A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL Polatuzumab vedotin, Rituximab, Cyclophosphamide - Diffuse Large B Cell Lymphoma | Phase 2 | Not yet recruiting | The First Affiliated Hospital with Nanjing Medical University | 528 | 2024-10-01 | 2024-07-24 |
| Neoadjuvant Therapy for Locally Advanced Rectal Cancer Anlotinib hydrochloride,Penpulimab - Colorectal Cancer | Early Phase 1 | Active not recruiting | The First Affiliated Hospital with Nanjing Medical University | 48 | 2024-09-01 | 2025-03-03 |
| Clinical Study of TQB2223 Injection Combined With AK105 Injection in the Treatment of Advanced Hepatocellular Carcinoma. TQB2223 injection, Penpulimab Injection - Advanced Hepatocellular Carcinoma | Phase 1 | Terminated | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 22 | 2024-05-30 | 2025-11-21 |
| TQB2928 Injection Combined With Penpulimab in Treatment of Advanced Malignant Tumors. TQB2928 injection, Penpulimab - Advanced Malignant Neoplasm | Phase 1 | Terminated | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 3 | 2024-05-24 | 2024-08-06 |
| Anlotinib Combined With Penpulimab as Front-line Treatment in Advanced Non-small Cell Lung Cancer anlotinib combined with penpulimab - Non-small Cell Lung Cancer | Phase 2 | Unknown | The First Affiliated Hospital of Zhengzhou University | 33 | 2024-01-31 | 2024-04-02 |
| A Clinical Study of TQB2618 Injection Monotherapy and Combination Regimen (With Penpulimab Injection ±Anlotinib Hydrochloride Capsules) in the Four or Later Lines of Treatment of Advanced Colorectal Cancer. TQB2618 injection, Penpulimab injection, Anlotinib hydrochloride capsules - Colorectal Cancer | Phase 1 | Unknown | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 75 | 2024-01-13 | 2024-01-23 |
| Study of Anlotinib in Patients With Radioiodine Refractory Differentiated Thyroid Cancer Anlotinib Hydrochloride Capsule and Penpulimab - Locally Advanced or Metastatic Radioiodine-refractory Differentiated Thyroid Carcinoma | Not applicable | Unknown | Peking Union Medical College Hospital | 10 | 2023-11-11 | 2023-10-02 |
| Penpulimab Combined With Chemotherapy for Neoadjuvant and Adjuvant Therapy in Patients With Resectable HNSCC Penpulimab injection, cisplatin, albumin-paclitaxel - Head and Neck Squamous Cell Carcinoma | Phase 2 | Active not recruiting | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | 72 | 2023-10-17 | 2026-09-30 |
| A Single Center, Single Arm Clinical Study on the Treatment of Advanced Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations and Failed EGFR TKIs With the Combination of Enrotinib and Paclitaxel Monoclonal Antibody Anlotinib, Penpulimab - Lung Cancer, TKI Resistance | Phase 3 | Unknown | Degan Lu | 52 | 2023-09-01 | 2023-09-21 |
| Anlotinib, Penpulimab and Capecitabine in Recurrent/Metastatic Nasopharyngeal Carcinoma The combination treatment of anlotinib, penpulimab and capecitabine. - Nasopharyngeal Neoplasms | Phase 2 | Active not recruiting | Sun Yat-sen University | 59 | 2023-09-01 | 2026-01-23 |
| A Clinical Study of TQB2618 Injection Combined With Penpulimab Injection and Anlotinib Hydrochloride Capsules for First-line Treatment of Advanced Hepatocellular Carcinoma (HCC). Penpulimab injection, TQB2618 injection, Anlotinib Hydrochloride Capsules - Advanced Hepatocellular Carcinoma | Phase 1 | Terminated | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 29 | 2023-08-15 | 2025-08-12 |
Showing 20 of 53. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (4) · Colorectal Neoplasms (4) · Squamous Cell Carcinoma of Head and Neck (4) · Lymphoma, Large B-Cell, Diffuse (3) · Carcinoma, Hepatocellular (2) · Lung Neoplasms (2) · Lymphoma (2) · Nasopharyngeal Carcinoma (2) · Small Cell Lung Carcinoma (2) · Stomach Neoplasms (2) · Breast Neoplasms (1) · Carcinoma (1) · Carcinoma, Squamous Cell (1) · Digestive System Diseases (1) · Esophageal Squamous Cell Carcinoma (1)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (10) · The First Affiliated Hospital with Nanjing Medical University (5) · Peking Union Medical College Hospital (4) · Akeso (3) · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (3) · The First Affiliated Hospital of Zhengzhou University (3) · West China Hospital (3) · Hunan Cancer Hospital (2) · Nanfang Hospital, Southern Medical University (2) · Ruijin Hospital (2) · WEI XU (2) · Anhui Provincial Cancer Hospital (1) · Beijing Friendship Hospital (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. (1)
China (43) · Australia (1) · Brazil (1) · Canada (1) · United States (1)
Anli Tong (1) · Chaosu Hu, MD (1) · Guonan Zhang (1) · Jianfeng Zhou (1) · Juan Du (1) · Jun Ma, M.D. (1) · Junxiang Wen, PhD, MD (1) · Ning-Ning Lu (1) · Nong Yang, PhD (1) · Qiyuan Bao, PhD, MD (1) · Ren Zhao, MD, PHD (1) · Ruixia Guo, Director (1) · Tao Sun, Doctor (1) · Tianxin Lin (1)
PMID 27413711, PMID 26028407, PMID 26291008, PMID 28196905, PMID 28486985, PMID 29438373, PMID 30280641, PMID 30419091, PMID 31590988, PMID 32599071, PMID 33333328, PMID 33433946, PMID 33538338, PMID 33791214, PMID 34327136, PMID 35576956, PMID 35875118, PMID 36166026, PMID 38022553, PMID 38460751, PMID 38844468, PMID 39267574, PMID 41656201, PMID 41672977, PMID 41946687, PMID 41963080, PMID 42268339, PMID 42486095